NEA Management Company, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001512848

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth Tilt how tags are computed

Q3 2026 · 25 positions · Total reported value $1.36B · Top-10 concentration 90.2% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 11.5% · 0 new · 2 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -15.2% · vs SPY -17.3% · Prev Value $1.59B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -3.1% · vs SPY -5.3% · Latest Value $1.36B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, NEA Management Company, LLC disclosed 25 equity positions with a combined reported value of $1.36B. The filing implies a focused portfolio: its ten largest positions account for 90.2% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt.

The largest disclosed positions as of Q3 2026 were MBX ($211.88M), SGP ($192.20M), TRVI ($189.34M). By sector, the heaviest allocations are Health Care 95.3%, Technology 4.7%.

Versus the prior quarter, NEA Management Company, LLC opened 0 new positions, trimmed 2 and fully exited 1, a turnover rate of 11.5% of positions. The portfolio's overlap with the prior quarter was 96% of names.

Of the 1 positions fully exited versus the prior quarter, the largest were KPTI ($5.64M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

No new positions this quarter.

Fully Exited (vs previous quarter)

  • KPTI KARYOPHARM THERAPEUTICS INC · prev qtr: $5.64M

Insider Transactions (Form 4)

Latest NEA Management Company, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

NEA Management Company, LLC is an investment management firm based in Menlo Park, California, with approximately $35.6 billion in assets under management. The firm discloses its U.S. equity portfolio through SEC 13F filings.

Investment Approach

As a registered investment advisor, NEA Management Company, LLC discloses its holdings of U.S. publicly traded stocks through SEC 13F filings. The firm's investment strategy focuses on equity markets.

Asset Classes

The firm's portfolio primarily consists of U.S. publicly traded stocks, with equity positions regularly disclosed through SEC 13F filings.

Key Information

  • Headquartered in Menlo Park, California
  • Approximately $35.6 billion in assets under management according to SEC Form ADV
  • Operates as a registered investment advisor
  • Discloses equity investments through SEC 13F filings

For official disclosures about NEA Management Company, LLC, please refer to SEC filings.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased exposure to Health Care (85.3% of top-10 vs. 83.5% prev quarter), particularly biotech/therapeutics, with no new additions. The focus on clinical-stage drug developers suggests a bullish view on healthcare innovation, though reduced GLUE indicates selective profit-taking. 2. Key moves: Only one reduction: GLUE (Monte Rosa Therapeutics) reduced by 13.0% (1M shares). No additions. 3. Portfolio structure: Active, high-conviction (top-10 = 85.3% of AUM), concentrated in healthcare (biotech/therapeutics), with modest tech exposure (COUR). High-risk appetite (small-cap, clinical-stage companies). 4. Per-holding one-liner: - MBX: MBX Biosciences (biotech, unverified) - SGP: Spyglass Pharma (biotech, unverified) - TRVI: Trevi Therapeutics (CNS biotech, unverified) - CELC: Celcuity (cancer diagnostics, unverified) - SVRA: Savara (pulmonary drugs, unverified) - ZBIO: Zenas Biopharma (unverified) - GLUE: Monte Rosa Therapeutics (protein degraders, unverified) - AUPH: Aurinia Pharmaceuticals (lupus drug, unverified) - COUR: Coursera (online edtech) - CRSP: CRISPR Therapeutics (gene editing) 5. Style summary: Concentrated healthcare-focused fund with no new buys, trimming only one position amid rising biotech weights.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 10:39

Sector Allocation

Health Care 95.3%
Technology 4.7%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 3.61M $211.88M 15.53%
15.53%
Hold
2 7.39M $192.20M 14.09%
14.09%
Hold
3 13.22M $189.34M 13.88%
13.88%
Hold
4 1.71M $136.02M 9.97%
9.97%
Hold
5 24.47M $126.27M 9.26%
9.26%
Hold
6 4.02M $108.51M 7.95%
7.95%
Hold
7 6.69M $79.84M 5.85%
5.85%
Reduce
8 3.97M $64.29M 4.71%
4.71%
Hold
9 12.87M $63.82M 4.68%
4.68%
Hold
10 1.06M $58.56M 4.29%
4.29%
Hold
11 4.12M $55.48M 4.07%
4.07%
Hold
12 1.96M $14.31M 1.05%
1.05%
Hold
13 1.30M $12.86M 0.94%
0.94%
Hold
14 3.23M $9.38M 0.69%
0.69%
Hold
15 3.57M $9.35M 0.69%
0.69%
Hold
16 1.71M $8.57M 0.63%
0.63%
Hold
17 4.45M $8.39M 0.61%
0.61%
Hold
18 1.46M $5.40M 0.40%
0.40%
Hold
19 1.95M $3.42M 0.25%
0.25%
Hold
20 1.63M $1.74M 0.13%
0.13%
Hold
21 464.40K $1.66M 0.12%
0.12%
Hold
22 478.55K $1.30M 0.10%
0.10%
Hold
23 3.78M $1.18M 0.09%
0.09%
Hold
24 50.01K $229.02K 0.02%
0.02%
Hold
25 12.50K $148.12K 0.01%
0.01%
Reduce

FAQ

What did NEA Management Company, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, NEA Management Company, LLC reported 25 equity positions worth $1.36B in aggregate; its largest disclosed positions were MBX ($211.88M), SGP ($192.20M), TRVI ($189.34M).

How large is NEA Management Company, LLC's portfolio?

NEA Management Company, LLC reported $1.36B of long equity holdings across 25 positions as of 2026-Q3. Top-10 holdings account for 90.2% of reported value.

What is NEA Management Company, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/nea-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →